Johnson & Johnson might announce a deal soon to buy Texas-based biotech Ollin Biosciences for $3.4 billion or more. Under the terms currently being explored, J&J could pay $2.2 billion in upfront cash to Ollin’s financial backers, plus an additional $1.2 billion tied to potential future achievement.
Ollin Biosciences raised $330 million in June to help finish testing its new eye medicine, OLN324, for treating Diabetic macular edema (DME) and wet age-related macular degeneration (AMD), which are considered causes of progressive vision loss.
However, neither J&J nor Ollin Biosciences responded to requests for comment. If the deal goes through, it will fit well with Johnson & Johnson’s overall plan to grow its medicine business by buying other companies.
Also Read: Rox Secures $100 Million at $1.3 Billion Valuation
Earlier this year, J&J bought a biotech company called Firefly Bio for $1 billion in cash to help grow its cancer treatments. Earlier, it bought major drugmaker, Intra-Cellular Therapies, for $14.6 billion in 2025 to strengthen its position in treatments for brain and nerve disorders.
Johnson & Johnson works to prevent and cure complex diseases, make treatments smarter and less invasive, and create personal solutions. They create solutions today as a focused healthcare company specialising in Innovative Medicine and MedTech. They improve health in special areas.
Manya Khurana is a Content Writer at TradeFlock with 2+ years of experience across finance, healthcare, and startup businesses. She has authored over 50 articles, with a focus on showcasing entrepreneurial journeys in a way that inspires readers. Her storytelling is grounded in numbers, blending narrative with data to give startups' stories real weight. She has covered several upcoming startups well before they gained recognition, using her evaluation of their early moves to spot which ones were worth writing about. in






